Phio net loss widens to $4.14 million in Q2 FY26
PHIO•Trial progress and near-term plans
PH-762 Phase 1b trial in skin cancers completed in March; final study documentation is being prepared for FDA submission.
Phio plans to request an FDA meeting in Q3 2026, while commercial-scale API work and long-term nonclinical study dosing target year-end completion.
Quarterly loss widens as R&D spending rises
Phio Pharmaceuticals posted a GAAP net loss of $4.1 million for the quarter ended June 30, 2026, widening from $2.2 million.
R&D expense more than doubled to $3.1 million, driven by higher nonclinical toxicology and CMC spending.
Cash and cash equivalents fell to $13 million at June 30, 2026 from $21 million at Dec. 31, 2025.
